<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04111133</url>
  </required_header>
  <id_info>
    <org_study_id>INT/IEC/2019/001617</org_study_id>
    <nct_id>NCT04111133</nct_id>
  </id_info>
  <brief_title>Ivabradine in Cirrhotic Cardiomyopathy</brief_title>
  <official_title>Efficacy of Carvedilol + Ivabradine vs Carvedilol Alone for Left Ventricular Diastolic Dysfunction in Chronic Liver Disease Patients and Its' Impact on Morbidity and Mortality; a Prospective Randomized Controlled Trial.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Postgraduate Institute of Medical Education and Research</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Postgraduate Institute of Medical Education and Research</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      A total of 130 patients with liver cirrhosis who fulfill the criteria of the study, and who&#xD;
      have been found to have left ventricular diastolic dysfunction on a screening 2D&#xD;
      echocardiography, will then be randomized by Block randomization technique, to two arms in a&#xD;
      ratio 1:1(Group A) will receive carvedilol+ Ivabradine targeted therapy for heart rate&#xD;
      reduction while Group B will receive Carvedilol alone; and the dosage of drug in the&#xD;
      treatment arm will be titrated every week to achieve target heart rate of 50-60/ minute.&#xD;
      Patients in the treatment arms, who are unable to tolerate carvedilol due to hypotension&#xD;
      episodes, will be offered ivabradine alone to allow achievement of targeted heart rate&#xD;
      reduction. All patients will be evaluated at 0,6, and 12 months. The end points will be&#xD;
      clinical events, cardiac function improvement, renal function, and mortality.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The investigators have already demonstrated the role of targeted heart rate reduction in the&#xD;
      management of LVDD in cirrhosis, but the previous study could not demonstrate the role of&#xD;
      ivabradine alone in absence of betablocker therapy. This trial will be a validation cohort&#xD;
      for the initial data obtained on this novel drug. The use of ivabradine can treat patients&#xD;
      who do not tolerate betablocker therapy due to contraindications or adverse effects&#xD;
      especially hypotension.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">January 1, 2020</start_date>
  <completion_date type="Anticipated">December 2022</completion_date>
  <primary_completion_date type="Anticipated">October 2021</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
    <masking_description>Open Label</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Number of Episodes of Cirrhosis related events</measure>
    <time_frame>12 months</time_frame>
    <description>New onset ascites, variceal bleeding,hepatorenal syndrome</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Survival</measure>
    <time_frame>12 months</time_frame>
    <description>All cause mortality to be assessed</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change in E/e' Ratio</measure>
    <time_frame>12 months</time_frame>
    <description>Echo parameter to be documented</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in renal function</measure>
    <time_frame>12 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in HRQoL</measure>
    <time_frame>12 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in neurohormonal markers- Brain natriuretic peptide, aldosterone, plasma renin activity</measure>
    <time_frame>12 months</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">130</enrollment>
  <condition>Cirrhotic Cardiomyopathy</condition>
  <condition>Left Ventricular Dysfunction</condition>
  <condition>Cirrhosis, Liver</condition>
  <condition>Portal Hypertension</condition>
  <arm_group>
    <arm_group_label>Carvedilol + Ivabradine</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Carvedilol</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Betablocker + ivabradine</intervention_name>
    <description>Use of maximum tolerated dose of carvedilol and ivabradine to achieve therapeutic heart rate reduction (THR) to 55-65 beats per minute</description>
    <arm_group_label>Carvedilol + Ivabradine</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Betablocker</intervention_name>
    <description>Use of maximum tolerated dose of carvedilol to achieve targeted heart rate reduction (THR) to 55-65 beats per minute (responder) or inability to reach THR (non responder) with maximum dose of carvedilol, maintaining a minimum MAP of 70 mmHg.</description>
    <arm_group_label>Carvedilol</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Age range of 18-65 years&#xD;
&#xD;
          -  Cirrhosis, as diagnosed by histology or clinical, laboratory and USG findings,&#xD;
&#xD;
          -  LV diastolic dysfunction on 2D echocardiography&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Chronic renal disease&#xD;
&#xD;
          -  Patient already on beta blocker&#xD;
&#xD;
          -  Pregnancy and peripartum cardiomyopathy&#xD;
&#xD;
          -  Hypertension&#xD;
&#xD;
          -  Coronary artery disease&#xD;
&#xD;
          -  Valvular heart disease&#xD;
&#xD;
          -  Sick sinus syndrome/ Pacemaker&#xD;
&#xD;
          -  Cardiac rhythm disorder&#xD;
&#xD;
          -  Hypothyroidism&#xD;
&#xD;
          -  Hyperthyroidism&#xD;
&#xD;
          -  Portal vein thrombosis&#xD;
&#xD;
          -  Transjugular intrahepatic porto systemic shunt (TIPS) insertion&#xD;
&#xD;
          -  Hepatocellular carcinoma&#xD;
&#xD;
          -  Anemia Hb &lt; 8gm/dl in females, and &lt; 9 gm/dl in males&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Radha K Dhiman, MD DM</last_name>
    <role>Study Chair</role>
    <affiliation>Postgraduate Institute of Medical Education and Research</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Madhumita Premkumar, MD DM</last_name>
    <phone>01722756344</phone>
    <email>drmadhumitap@gmail.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Postgraduate Institute of Medical Education and Research</name>
      <address>
        <city>Chandigarh</city>
        <state>Choose Any State/Province</state>
        <zip>160012</zip>
        <country>India</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Madhumita Premkumar</last_name>
    </contact>
  </location>
  <location_countries>
    <country>India</country>
  </location_countries>
  <verification_date>September 2021</verification_date>
  <study_first_submitted>September 26, 2019</study_first_submitted>
  <study_first_submitted_qc>September 28, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">October 1, 2019</study_first_posted>
  <last_update_submitted>September 26, 2021</last_update_submitted>
  <last_update_submitted_qc>September 26, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">October 4, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Postgraduate Institute of Medical Education and Research</investigator_affiliation>
    <investigator_full_name>Madhumita Premkumar</investigator_full_name>
    <investigator_title>Assistant Professor and Principal Investigator, Department of Hepatology</investigator_title>
  </responsible_party>
  <keyword>Cirrhotic cardiomyopathy</keyword>
  <keyword>Left ventricular diatolic dysfunction</keyword>
  <keyword>Carvedilol</keyword>
  <keyword>Ivabradine</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hypertension, Portal</mesh_term>
    <mesh_term>Liver Cirrhosis</mesh_term>
    <mesh_term>Cardiomyopathies</mesh_term>
    <mesh_term>Ventricular Dysfunction</mesh_term>
    <mesh_term>Ventricular Dysfunction, Left</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Adrenergic beta-Antagonists</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

